Clinical Trial Update: Valganciclovir in Prevention of Cytomegalovirus (CMV) Reactivation Following Allogeneic-Stem Cell Transplantation (SCT) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating valganciclovir to prevent CMV reactivation after allogeneic stem cell transplantation has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Infection

Drugs mentioned

• Valcyte (valganciclovir)

Snippet

Sponsor: Hadassah Medical Organization | Conditions: Bone Marrow Transplantation, Cytomegalovirus | Phase 3 | Status: COMPLETED